Intra-cellular Drug Patent Portfolio

Intra-cellular owns 1 orange book drug protected by 22 US patents Given below is the list of Intra-cellular's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11753419 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)phenyl)butan-1-one for treating conditions of the central nervous system and cardiac disorders 10 Dec, 2040
Active
US11980617 Methods of treating acute depression and/or acute anxiety 27 Oct, 2039
Active
US10695345 Pharmaceutical capsule compositions comprising lumateperone mono-tosylate 30 Aug, 2039
Active
US11052084 Pharmaceutical capsule compositions comprising lumateperone mono-tosylate 30 Aug, 2039
Active
US11690842 Pharmaceutical capsule compositions comprising lumateperone mono-tosylate 30 Aug, 2039
Active
US11806348 Methods of treatment using pharmaceutical capsule compositions comprising lumateperone mono-tosylate 30 Aug, 2039
Active
US12070459 Pharmaceutical capsule compositions comprising lumateperone mono-tosylate 30 Aug, 2039
Active
US10960009 Methods of treating schizophrenia and depression 03 Dec, 2034
Active
US11026951 Methods of treating bipolar disorder 03 Dec, 2034
Active
US9956227 Method for the treatment of residual symptoms of schizophrenia 03 Dec, 2034
Active
USRE48839 Methods and compositions for sleep disorders and other disorders 19 Aug, 2033
Active
US8598119 Methods and compositions for sleep disorders and other disorders 28 Dec, 2029
Active
US8648077 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid addition salt and salt crystals 01 Dec, 2029
Active
US10117867 Methods and compositions for sleep disorders and other disorders 27 May, 2029
Active
US9168258 Methods and compositions for sleep disorders and other disorders 27 May, 2029
Active
US9616061 Methods and compositions for sleep disorders and other disorders 27 May, 2029
Active
US9199995 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid addition salt and salt crystals 12 Mar, 2029
Active
US9586960 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de] quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid salt crystal forms 12 Mar, 2029
Active
USRE48825 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid salt crystal forms 12 Mar, 2029
Active
US10464938 Pharmaceutical compositions comprising ((6bR,10aS)-1-(4-fluorophenyl)-4-(3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)butan-1-one or pharmaceutically acceptable salts thereof 12 Mar, 2028
Active
US7183282 Substituted heterocycle fused γ-carbolines 15 Jun, 2020 Expired
USRE39680 Substituted heterocycle fused gamma-carbolines 15 Jun, 2020 Expired


Given below is the list of recent legal activities going on the following drug patents of Intra-cellular.

Activity Date Patent Number
Patent litigations
Patent eCofC Notification 30 Jan, 2024 US11806348
Mail Patent eCofC Notification 30 Jan, 2024 US11806348
Email Notification 30 Jan, 2024 US11806348
Recordation of Patent eCertificate of Correction 30 Jan, 2024 US11806348
Post Issue Communication - Certificate of Correction 10 Jan, 2024 US11806348
Payment of Maintenance Fee, 4th Year, Large Entity 30 Nov, 2023 US10695345
Patent Issue Date Used in PTA Calculation 07 Nov, 2023 US11806348
Email Notification 07 Nov, 2023 US11806348
Recordation of Patent eGrant 07 Nov, 2023 US11806348
Mail Patent eGrant Notification 07 Nov, 2023 US11806348
Recordation of Patent Grant Mailed 07 Nov, 2023 US11806348
Patent eGrant Notification 07 Nov, 2023 US11806348
Email Notification 31 Oct, 2023 US11690842
Mail Pub Notice re 312 amendment 31 Oct, 2023 US11690842
Post Issue Communication - Certificate of Correction 27 Oct, 2023 US11690842


Intra-cellular Drug Patents' Oppositions Filed in EPO

Intra-cellular drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Apr 27, 2022, by Sandoz Ag. This opposition was filed on patent number EP14867061A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP14867061A Apr, 2022 Sandoz AG Granted and Under Opposition


Intra-cellular's Family Patents

Intra-cellular drugs have patent protection in a total of 20 countries. It's US patent count contributes only to 32.5% of its total global patent coverage. Click below to unlock the full patent family tree.

Family Patents



Intra-cellular Drug List

Given below is the complete list of Intra-cellular's drugs and the patents protecting them.


1. Caplyta

Caplyta is protected by 23 patents, out of which 2 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11753419 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)phenyl)butan-1-one for treating conditions of the central nervous system and cardiac disorders 10 Dec, 2040
(16 years from now)
Active
US11980617 Methods of treating acute depression and/or acute anxiety 27 Oct, 2039
(15 years from now)
Active
US10695345 Pharmaceutical capsule compositions comprising lumateperone mono-tosylate 30 Aug, 2039
(14 years from now)
Active
US11052084 Pharmaceutical capsule compositions comprising lumateperone mono-tosylate 30 Aug, 2039
(14 years from now)
Active
US11690842 Pharmaceutical capsule compositions comprising lumateperone mono-tosylate 30 Aug, 2039
(14 years from now)
Active
US11806348 Methods of treatment using pharmaceutical capsule compositions comprising lumateperone mono-tosylate 30 Aug, 2039
(14 years from now)
Active
US12070459 Pharmaceutical capsule compositions comprising lumateperone mono-tosylate 30 Aug, 2039
(14 years from now)
Active
US10960009 Methods of treating schizophrenia and depression 03 Dec, 2034
(10 years from now)
Active
US11026951 Methods of treating bipolar disorder 03 Dec, 2034
(10 years from now)
Active
US9956227 Method for the treatment of residual symptoms of schizophrenia 03 Dec, 2034
(10 years from now)
Active
USRE48839 Methods and compositions for sleep disorders and other disorders 19 Aug, 2033
(8 years from now)
Active
US8598119 Methods and compositions for sleep disorders and other disorders 28 Dec, 2029
(5 years from now)
Active
US8648077 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid addition salt and salt crystals 01 Dec, 2029
(5 years from now)
Active
US10117867 Methods and compositions for sleep disorders and other disorders 27 May, 2029
(4 years from now)
Active
US9168258 Methods and compositions for sleep disorders and other disorders 27 May, 2029
(4 years from now)
Active
US9616061 Methods and compositions for sleep disorders and other disorders 27 May, 2029
(4 years from now)
Active
US9199995 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid addition salt and salt crystals 12 Mar, 2029
(4 years from now)
Active
US9586960 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de] quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid salt crystal forms 12 Mar, 2029
(4 years from now)
Active
USRE48825 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid salt crystal forms 12 Mar, 2029
(4 years from now)
Active
USRE48825 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid salt crystal forms 12 Feb, 2029
(4 years from now)
Active
US10464938 Pharmaceutical compositions comprising ((6bR,10aS)-1-(4-fluorophenyl)-4-(3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)butan-1-one or pharmaceutically acceptable salts thereof 12 Mar, 2028
(3 years from now)
Active
US7183282 Substituted heterocycle fused γ-carbolines 15 Jun, 2020
(4 years ago)
Expired
USRE39680 Substituted heterocycle fused gamma-carbolines 15 Jun, 2020
(4 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Caplyta's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List